Metabolic parameters like body weight, blood pressure, cholesterol and blood sugar levels are established risk factors for cardiovascular disease. But a new study suggests it’s not just abnormal measures of these components that portend risk—significant fluctuations in these areas are independently linked to all-cause mortality, heart attack and stroke among otherwise healthy people.

An increased intake of vitamin B, paired with routine ACE inhibitor therapy, could help protect kidney function in kids and teens with type 1 diabetes (T1D), according to a study presented at the 57th annual European Society for Pediatric Endocrinology Meeting in Athens, Greece.

Though they might provide some benefit to high-risk patients in the month after a heart attack, wearable cardioverter-defibrillators don’t significantly lower the rate of arrhythmic death in those who have suffered myocardial infarctions, according to work published in the New England Journal of Medicine Sept. 27.

A Hillsborough County Fire Rescue paramedic has been fired and three others suspended without pay after a 10-week investigation concluded they failed to adequately care for a stroke patient who later died, the Tampa Bay Times reported this week.

A press conference at the 2018 Transcatheter Cardiovascular Therapeutics meeting in San Diego on Tuesday, Sept. 25, morphed into a discussion about the future of bioresorbable vascular scaffolds (BVS) and whether it’s worth pursuing bioresorbable stent technology at all.

Targeted plasticity therapy (TPT)—a novel approach to stroke treatment that involves stimulating the vagus nerve to accelerate plasticity in the brain—can double stroke patients’ rates of upper limb recovery, according to research published in Stroke. Paired with traditional motor-skill rehabilitation, it’s twice as effective as standard therapy.

Heart failure (HF) patients who experience moderate functional mitral regurgitation (FMR) for at least six months after cardiac resynchronization therapy (CRT) are at an increased risk for death, researchers suggest in a study published this week.

Acute coronary syndrome patients who were given a loading dose of atorvastatin before percutaneous coronary intervention (PCI) experienced a 28 percent reduction in major adverse cardiovascular events (MACE) over the following 30 days, according to a secondary analysis of the randomized SECURE-PCI trial published in JAMA Cardiology.